AntriaBio, Inc. (OTCQB: ANTB) is a biopharmaceutical company focused on developing novel therapeutics to treat patients with diabetes and metabolic disease. AB101, AntriaBio’s lead product candidate, is an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes. AntriaBio’s development strategy combines FDA-approved pharmaceutical agents with the company’s proprietary delivery technology. One of the company’s central patents and patent applications is for the conjugation of bioactive agents, including insulin; this underlying technology is approved in Europe and Australia and is patent pending in the U.S., Canada, Japan, China, Hong Kong, Brazil and India. For more information, visit the company’s website at www.antriabio.com